GENECAST

Merck has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients. The study targets those with KRAS G12C mutations and high PD-L1 expression (TPS ≥50%). This trial aims to build on early evidence of manageable safety and promising anti-tumor activity, enrolling approximately 600 patients globally to assess progression-free survival and overall survival outcomes. 🔗Check out the full article from the link on comment🔗 #ClinicalTrial #KRASG12C #LungCancer #CancerResearch #Oncology #NSCLC #GENECAST #ADPS #LiquidBiopsy #CancerDiagnosis #CancerDetection

GENECAST has come to collaborate with Medicheck, the largest health screening institution in Korea, on early cancer detection through liquid biopsy.🌟 #GENECAST #MediCheck #LiquidBiopsy #EarlyCancerDetection #HealthcareInnovation #CancerDiagnostics

The combination of encorafenib and binimetinib, which received FDA approval in October 2023, has now released additional long-term efficacy data on treatment outcomes and durability. In particular, the PHAROS trial reported an objective response rate (ORR) of 75% in treatment-naïve patients after 33.3 months of follow-up, with a duration of response (DOR) of 40 months. This demonstrates a longer duration of treatment response compared to previous data. For more details, read full article here🔗 https://lnkd.in/gP6V2SYw #CancerResearch #Oncology #ClinicalData #TreatmentOutcomes #CancerTreatment #GENECAST #ADPS #LiquidBiopsy #CancerDiagnosis #CancerDetection

On September 25, 2024, the FDA announced the approval of osimertinib (Tagrisso) by AstraZeneca as a treatment for patients with stage III unresectable non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. Osimertinib (Tagrisso) is already well known as a treatment for NSCLC patients with EGFR mutations. However, the FDA approval on September 25, 2024, represents a new option for stage III unresectable lung cancer patients following chemoradiation therapy. While previous approvals primarily targeted advanced or metastatic lung cancer, this update expands the use of Tagrisso to locally advanced patients whose disease has not progressed after treatment. As a result, this news is significant as it offers a new treatment option for patients with stage III unresectable NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations, following chemoradiation therapy. Check out the full article from the link on comment #Osimertinib #LungCancer #NSCLC #EGFRMutations #CancerTreatment #Oncology #GENECAST #ADPS #LiquidBiopsy #CancerDiagnosis #CancerDetection

Amgen has announced the combination therapy of sotorasib(LUMAKRAS®) and panitumumab(Vectibix®) for metastatic colorectal cancer (mCRC) patients with KRAS G12C mutations through the CodeBreaK 300 study. According to data presented by an independent research team supported by Amgen, this combination significantly improved the progression-free survival (PFS) of patients who had shown resistance to prior chemotherapy. At the 960 mg dose, PFS was 5.6 months, a substantial improvement compared to 2.2 months in the standard treatment group. In terms of objective response rate (ORR), while the standard treatment group saw no response, the ORR was reported as 26% in the 960 mg combination and 6% in the 240 mg combination. Notably, the tumor reduction rate in the 960 mg combination reached 81%, which is significantly higher compared to 20% in the standard treatment group. These results suggest that this combination therapy could offer a new treatment option for mCRC patients with KRAS G12C mutations. The data was also presented at both ASCO and ESMO. Based on these findings, Amgen appears to be planning additional regulatory approval processes. #KRASG12C #ColorectalCancer #CancerResearch #Oncology #CancerTreatment #ESMO #ASCO #Genecast #ADPS #LiquidBiopsy #CancerDiagnosis #CancerDetection

🚀 GENECAST Website & Product Line Updated! 🚀 We are excited to announce the renewal of the GENECAST website, along with the latest updates to our product line. Our website now offers a refreshed user experience, making it easier for you to explore and understand our technology and products. Additionally, our updated product line has upgraded powered by core technology ADPS™. Explore the new site and discover new face of GENECAST. 🔗www.igenecast.com🔗 #GENECAST #ADPS #LiquidBiopsy #CancerDiagnostics #CancerDetection #Innovation

Breast Cancer Awareness Month October October is Breast Cancer Awareness Month. This campaign aims to raise awareness, encourage early detection, and support research related to breast cancer. At GENECAST, we contribute to breast cancer research and diagnostics through our highly sensitive liquid biopsy technology. #BreastCancerAwarenessMonth #EarlyDetection #BreastCancerResearch #LiquidBiopsy #GENECAST

🌍 GENECAST participated in the Indonesia International Cancer Conference (IICC) 2024 (October 3rd - 5th, 2024), where we introduced our innovative cancer diagnostic technology, ADPS™. ADPS is a PCR-based technology that cancels out background noise, achieving ultra-high sensitivity and enabling the diagnosis of patients with MAF of up to 0.01%. #IICC2024 #GENECAST #ADPS #LiquidBiopsy #CancerDetection #CancerDiagnostics

GENECAST has developed ADPS™ to enhance cancer diagnostics and treatment. With ADPS™ we have maximized ctDNA detection sensitivity. And by enabling early detection and precise monitoring, we aim to support clinical professionals in providing personalized and effective treatment for patients. #Genecast #ADPS #LiquidBiopsy #CancerDiagnosis #CancerDetection  #PrecisionMedicine #PersonalizedMedicine #EarlyDetection #CancerResearch #SmartDNAPolymerase #CancerTreatment #MedicalTechnology #ClinicalDiagnostics

Wishing You a Joyful Chuseok 🎑 As Chuseok approaches, a meaningful holiday in Korea similar to Thanksgiving, we want to send our warmest wishes to you. We wish you and your loved ones a season filled with happiness and good health. We are truly thankful for your continued partnership and support throughout the year. Best regards, The Genecast Team